The market will continue to witness double-digit growth, with demand largely driven by first-generation products such as Rh protein therapeutics and monoclonal antibodies targeted for cancer treatment.
So says Frost & Sullivan in a new report called “Global Biopharmaceutical Contract Manufacturing Markets” (www.pharmaceutical.frost.com). The report finds that the markets earned revenues of $2.45 billion in 2007. They are estimated to grow to $6.48 billion by 2014.
Companies in this article
